The Synthesis and Antiviral Properties of Acyclic Nucleoside Analogues with a Phosphonomethoxy Fragment in the Side Chain

Abstract

ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.

Third-Generation Immucillins: Syntheses and Bioactivities of Acyclic Immucillin Inhibitors of Human Purine Nucleoside Phosphorylase

“…1 H NMR (CD 3 OD): δ 7.32-7.18 (m, 5H), 3.93 (dd, J ) 12.0, 6.0 Hz, 2H), 3.72 (s, 2H), 3.64 (dd, J ) 12.0, 6.0 Hz, 2H), 2.54 (d, J ) 6.0 Hz, 2H), 1.89 (m, 1H), 1.31 (s, 6H). (27). Acetic acid (0.122 mL, 2.13 mmol) was added dropwise to a solution of compound 81 (100 mg, 0.43 mmol) in 1,4-dioxane (2 mL) followed by 9-deazahypoxanthine (75) 10 (115 mg, 0.85 mmol) and the resulting suspension heated at 95 °C (bath temperature) for 16 h. After cooling to room temperature silica gel (1.0 g) was added and the mixture concentrated in vacuo.…”

“…Since the discovery of the antiviral drug 9-[(2-hydroxyethoxy)methyl]guanine (acyclovir) some 30 years ago, , there has been considerable interest and research into acyclic nucleoside analogues and their efficacy as antiviral and anticancer drugs. − We recently communicated the biological activities of several acyclic derivatives , of which DATMe-ImmH ( 11 ) was found to be a surprisingly potent inhibitor. Prompted by this exciting discovery, we elected to explore the SAR of acyclic immucillin derivatives in more detail.…”

Analogues of Pyrimidine Nucleosides as Mycobacteria Growth Inhibitors

“…It can be assumed that the inhibitory activity of 5-alkyloxymethyl toxicity of the drug. This approach helps in the effective delivery of the drug to the target of action and improves its pharmacokinetic characteristics due to the slower release of the active component [67][68][69][70][71][72][73].…”

“…One of the ways to overcome this obstacle is the synthesis of depot forms (“prodrugs”) (The term depot form means a biologically inert or weakly active compound containing the parent drug, which undergoes transformation in vivo due to chemical or enzymatic cleavage to release the parent drug), which can be used to improve the pharmacokinetics, pharmacodynamics, solubility and toxicity of the drug. This approach helps in the effective delivery of the drug to the target of action and improves its pharmacokinetic characteristics due to the slower release of the active component [ 67 , 68 , 69 , 70 , 71 , 72 , 73 ].…”

Pyrimidine Nucleosides Analogues as Mycobacteria Growth Inhibitors

“…One of the ways to overcome this obstacle is the synthesis of depot forms ("prodrugs") (The term depot form means a biologically inert or weakly active compound containing the parent drug, which undergoes transformation in vivo due to chemical or enzymatic cleavage to release the parent drug), which can be used to improve the pharmacokinetics, pharmacodynamics, solubility and toxicity of the drug. This approach helps in the effective delivery of the drug to the target www.videleaf.com of action and improves its pharmacokinetic characteristics due to the slower release of the active component [65][66][67][68][69][70][71].…”